Menu Search
Equities

Aspira Women's Health Inc

CULG:DEU

Aspira Women's Health Inc

Actions
  • Price (EUR)0.62
  • Today's Change-0.005 / -0.80%
  • Shares traded0.00
  • 1 Year change-79.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aspira Women's Health Inc grew revenues 11.85% from 8.18m to 9.15m while net income improved from a loss of 29.89m to a smaller loss of 16.69m.
Gross margin57.84%
Net profit margin-178.80%
Operating margin-183.28%
Return on assets-273.16%
Return on equity--
Return on investment-3,758.30%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Aspira Women's Health Inc fell by 10.70m. Cash Flow from Financing totalled 5.22m or 56.98% of revenues. In addition the company used 15.89m for operations while cash used for investing totalled 24.00k.
Cash flow per share-1.42
Price/Cash flow per share--
Book value per share-0.2892
Tangible book value per share-0.2892
More ▼

Balance sheet in USDView more

Aspira Women's Health Inc uses little or no debt in its capital structure.
Current ratio0.5956
Quick ratio0.5542
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.